EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma

Satoshi Katayama iD, Tatsushi Kawada iD, Keiichiro Mori iD, Kosuke Iwatani, Shota Inoue iD, Tomofumi Watanabe iD, Ichiro Tsuboi iD, Tomoaki Yamanoi iD, Takehiro Iwata iD, Kazuma Tsuboi iD, Wataru Murao, Tetsuya Nakada und 8 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70664 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Satoshi Katayama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ureteral Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).

Methods

This multicenter study comprised 97 patients undergoing removal of primary tumors, followed by adjuvant nivolumab therapy with a potential follow‐up period ≥ 12 months. Patients were divided according to the primary tumor location: bladder cancer (BC), n = 66 (68%); UTUC, n = 31 (32%). Multivariable Cox regression analyses were applied to identify prognostic factors for disease‐free survival (DFS).

Results

Before surgery, 38% of patients had an estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m 2 , but this proportion increased to 57% at nivolumab initiation with 19% of UTUC having eGFR < 30. The overall DFS at 6 months was 61.5%. DFS did not differ significantly between BC and UTUC ( p = 0.83). On multivariable analyses, a higher absolute eosinophil count was significantly associated with worse DFS (HR 2.24; 95% CI, 1.24–4.03, p = 0.007), while primary tumor location was not. Immune‐related adverse events (irAEs) of adrenal insufficiency and hypophysitis occurred in 8% and 4% of patients, respectively, with grade ≥ 3 occurring at 3.3–18.3 months.

Conclusions

Adjuvant nivolumab therapy may provide comparable oncological outcomes between BC and UTUC. Baseline eosinophil count was an independent prognosticator for DFS. The incidences of adrenal insufficiency and hypophysitis appeared higher in our real‐world data. Clinicians should recognize these irAEs due to nonspecific symptoms and considerable variability in time of onset.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Transitional CellUrinary Bladder NeoplasmsUreteral NeoplasmsKidney NeoplasmsImmune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalHumansFemaleMaleAgedDisease-Free SurvivalChemotherapy, AdjuvantRetrospective StudiesNeoplasm InvasivenessTreatment OutcomeMiddle AgedAged, 80 and overPrognosisGlomerular Filtration RateEosinophilsCystectomy

Stichwörter der Autor:innen

adjuvant nivolumabeosinophilhypophysitisupper tract urothelial carcinomaurothelial carcinoma

Substanzen

NivolumabImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Urology, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan.
  • Department of Urology, Shimane University Hospital, Shimane, Japan.

ORCID-Profile: Satoshi Katayama, Tatsushi Kawada, Keiichiro Mori, Shota Inoue, Tomofumi Watanabe, Ichiro Tsuboi, Tomoaki Yamanoi, Takehiro Iwata, Kazuma Tsuboi, Kohei Ogawa, Akihiro Matsukawa, Takafumi Yanagisawa, Shingo Nishimura, Kensuke Bekku, Koichiro Wada, Takahiro Kimura, Motoo Araki

Zitieren

APA

Katayama, S., Kawada, T., Mori, K., Iwatani, K., Inoue, S., Watanabe, T., Tsuboi, I., Yamanoi, T., Iwata, T., Tsuboi, K., Murao, W., Nakada, T., Ogawa, K., Matsukawa, A., Yanagisawa, T., Nishimura, S., Bekku, K., Wada, K., Kimura, T., & Araki, M. (2026). Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70664

Vancouver

Katayama S, Kawada T, Mori K, Iwatani K, Inoue S, Watanabe T, et al. Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma. International Journal of Urology. 2026. doi:10.1111/iju.70664

BibTeX
@article{Katayama2026,
  author = {Katayama, Satoshi and Kawada, Tatsushi and Mori, Keiichiro and Iwatani, Kosuke and Inoue, Shota and Watanabe, Tomofumi and Tsuboi, Ichiro and Yamanoi, Tomoaki and Iwata, Takehiro and Tsuboi, Kazuma and Murao, Wataru and Nakada, Tetsuya and Ogawa, Kohei and Matsukawa, Akihiro and Yanagisawa, Takafumi and Nishimura, Shingo and Bekku, Kensuke and Wada, Koichiro and Kimura, Takahiro and Araki, Motoo},
  title = {Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70664}
}
Kostenlos starten →